All patients began treatment in the extension study with SXB 4.5 g/night ( administered in 2 equally divided doses ) for at least 1 week , followed by possible serial 1.5 g/night dose increases to 9 g/night ( maximum ) or reductions to 4.5 g/night ( minimum ) .